• Sequenom Inc., of San Diego, said it intends to offer $100 million of convertible senior notes due 2017 in a private offering. It also will grant initial purchasers of the convertible notes a 30-day option to purchase up to an additional $20 million of the notes to cover overallotments. The company said it intends to direct some of the net proceeds from the offering to fund the commercialization of its MaterniT21 PLUS laboratory-developed test, which analyzes the relative amount of chromosomes 21, 18 and 13 in circulating cell-free DNA from a maternal blood sample. In trading Tuesday, the company's stock (NASDAQ:SQNM) closed at $3.63, down 28 cents.

• Tengion Inc., of Winston-Salem, N.C., said it arranged a one-month bridge loan with leading investors. The loan is expected to facilitate a further $15 million of convertible debt later this month. The company also reported that a sixth patient has been successfully implanted in the ongoing Phase 1 trial of its Neo-Urinary Conduit, for use in bladder cancer patients requiring a urinary diversion following bladder removal. The trial is designed to assess the safety and preliminary efficacy of the Neo-Urinary Conduit in up to 10 patients, as well as to translate the surgical procedure successfully used in preclinical animal models into clinical trials with human patients. The news vaulted the company's share price (NASDAQ:TNGN), which jumped 58 cents, or 48.3 percent, to close Tuesday at $1.78.